Lead: A µ-opioid receptor superagonist analgesic with minimal adverse effectsLead: A µ-opioid receptor superagonist analgesic with minimal adverse effects
This Week in Addiction Medicine from ASAM
A rapid news briefing covers new research on an experimental opioid analgesic, youth e-cigarette use, hazardous drinking, non-drug rewards in recovery, treatment facility costs, psychedelic brain effects, hepatitis C testing in a tribal setting, and mobile medications for opioid use disorder. The episode targets busy addiction professionals and those interested in current evidence around addiction treatment and harm reduction.
7:16•21 Apr 2026
Science in Minutes: Opioid Superagonists, E-Cigs, Psychedelics and More
Episode Overview
- DFNZ, a nitazene-derived µ-opioid receptor agonist, showed strong analgesia in rodents without respiratory depression, tolerance, or MOR downregulation.
- One-year patterns of e-cigarette use in adolescents and young adults were not significantly linked to dichotomous respiratory outcomes in adjusted analyses.
- Incentive salience within the addictions neuroclinical assessment framework correlated strongly with hazardous drinking across two samples.
- People in long-term recovery from opioid use disorder reported more non-drug rewards when they felt higher motivation and better access to rewarding activities.
- Private equity-owned residential SUD facilities had higher daily rates and were less likely to offer detox services in private rooms than other for-profit centres.
“These results provide novel insights about MOR and nitazine pharmacology, have important implications for pain and addiction treatment, and challenge the prevailing dogma that high-efficacy MOR agonists cannot constitute safe and effective therapeutic agents.”
How do people find strength in their journey to sobriety? This weekly news round-up from the American Society of Addiction Medicine gives clinicians, researchers, and anyone curious about evidence-based care a fast, research-heavy snapshot of what’s happening in addiction medicine. Hosted by Zach Caruso, the episode races through several new studies, starting with a potential game-changer in pain management: N-desethyl-fluornitrazene (DFNZ), a nitazene-derived µ-opioid receptor agonist.
As the summary notes, "These results provide novel insights about MOR and nitazine pharmacology, have important implications for pain and addiction treatment, and challenge the prevailing dogma that high-efficacy MOR agonists cannot constitute safe and effective therapeutic agents." From there, the episode moves into youth e-cigarette use, showing no statistically significant link between one-year use patterns and dichotomous respiratory outcomes in 15–24 year olds, then shifts to hazardous drinking, where machine learning supports the addictions neuroclinical assessment framework by tying incentive salience closely to risky alcohol use.
In rodents, DFNZ produced strong pain relief without classic opioid problems like respiratory depression or tolerance. You’ll also hear about non-drug rewards in long-term opioid use disorder recovery, where simple pleasures like relaxing at home show up as the most common daily rewards. Economic and structural issues appear too, with private equity-owned residential treatment facilities charging higher daily rates than other for-profit centres.
Later segments cover shared brain network effects of psychedelics, point-of-care hepatitis C testing in a Cherokee Nation harm reduction setting, and a mobile medications for opioid use disorder unit described as "a lifeline on wheels" for people facing homelessness and other barriers. If you like your addiction content short, fast, and science-first, this briefing packs a week’s worth of research into a few efficient minutes, perfect for staying up to date between clinics or support sessions.
Which of these findings feels most relevant to your work or recovery journey right now?
Do you want to link to this podcast?
Get the buttons here!
More From This Show
The latest episodes from the same podcast.
Related Episodes
Similar episodes from other shows in the catalogue.